Enterprise Value
12.81B
Cash
2.708B
Avg Qtr Burn
N/A
Short % of Float
10.25%
Insider Ownership
1.85%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tyvaso DPI™ (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3 | Approved Quarterly sales | |
Tyvaso (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 3 | Approved Quarterly sales | |
Remunity™ (treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH) | Approved Quarterly sales | |
Tyvaso (inhaled treprostinil) Details Progressive pulmonary fibrosis | Phase 3 Data readout | |
Tyvaso (inhaled treprostinil) Details Idiopathic pulmonary fibrosis, Pulmonary fibrosis | Phase 3 Data readout | |
Ralinepag (IP receptor agonist) Details Pulmonary hypertension | Phase 3 Data readout | |
Trevyent® (treprostinil sodium) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH) | Failed Discontinued | |
Tyvaso (inhaled treprostinil) Details Pulmonary hypertension, Chronic obstructive pulmonary disease | Failed Discontinued |